Drug Trial Radar · NCT04781725
INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
90
Planned (sponsor's estimate)
Start
Mar 25, 2021
Primary completion
Mar 1, 2022
Study completion Mar 1, 2023
Sponsor
- Lead sponsor
- Ottawa Hospital Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Intensity Therapeutics, Inc.; Ontario Institute for Cancer Research
- First posted
- Mar 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase II, randomized, multi-center, parallel design, window of opportunity trial evaluating intratumoral INT230-6 in up to 90 patients with early stage breast cancer. In a 2:1 randomization, patients on the treatment arm will receive intratumoral INT230-6 injections prior to breast surgery.
Conditions
- Breast Cancer
Interventions
INT230-6Drug
INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).
Saline injectionOther
Standard 0.9 % NaCl Normal Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients achieving a CCCA defined as a reduction in the proportion of cells staining positive for Ki67 as assessed by immunohistochemistry to less than a natural logarithm, or ≤2.7%, at the post-treatment specimen.Time frame: presurgical window (period from diagnosis to surgery window of 3-6 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Ottawa Hospital Research Institute and Cancer Center
Ottawa, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.